Article Details
Retrieved on: 2024-07-02 21:13:55
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the European Medicines Agency's CHMP rejecting marketing authorisation for pegcetacoplan, an AMD treatment, despite some support. Apellis Pharmaceuticals plans to seek re-examination. This links to tags on regulatory processes and drug development.
Article found on: www.optometrytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here